Project II: Biologics Engineering and Antibody Mechanism of Action

项目二:生物制剂工程与抗体作用机制

基本信息

  • 批准号:
    10088393
  • 负责人:
  • 金额:
    $ 166.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-02-14 至 2024-01-31
  • 项目状态:
    已结题

项目摘要

The rapid discovery of human monoclonal antibodies (mAbs) that arise during natural viral infection is central to the Prometheus consortium for developing immunoprophylactic and therapeutic medical countermeasures (MCMs). Our Center of Excellence for Translational Research will focus on developing MCMs for three groups of NIAID Category A priority pathogens (ebolaviruses, Crimean-Congo hemorrhagic fever virus, and hantaviruses). Ebolaviruses, members of the family Filoviridae, cause severe hemorrhagic fever in humans and non-human primates, with human case-fatality rates of up to 90%. As demonstrated by the 2013– 2016 epidemic of Ebola virus disease in West Africa, ebolaviruses pose a significant public health threat. Crimean-Congo hemorrhagic fever virus is a member of the Bunyaviridae family and induces fatal hemorrhaging in up to 50% of human infections. Hantaviruses also belong to the Bunyaviridae family, and infections are associated with over 150,000 cases of disease annually with case-fatality rates >30%. Given the disease severity caused by these viruses, MCMs are urgently needed. The protective efficacy of hyperimmune serum in animal models and humans strongly suggests that human infection and disease by these groups of viruses will be amenable to treatment with mAb-based therapeutics and prophylactics. Project II will facilitate mAb discovery efforts in Project I via the development of molecular tools (Aim 1) required to isolate and characterize candidate therapeutic mAbs from human survivors. Our focus will be on the generation of novel recombinant antigens and BSL-2 viral surrogates to use as probes in single B- cell sorting experiments. These biologics are also vital to the characterization process (Aim 2) that will define mAb epitopes, competition groups, structures, and mechanisms of action, as well as future product assay development in Core B. The data generated by Project II, combined with potency and synergy data from Project I, will allow for a streamlined and mechanistically informed down-selection of the most promising candidate mAbs and mAb combinations for in depth Fc-effector function analyses and optimization (Aim 3) prior to in vivo evaluation of leads by Core C. Project II will also be involved in finalizing the optimal lead immunoprophylactic mAbs to advance in Project III and immunotherapeutic mAbs to enter advanced development within Core B.
自然病毒过程中出现的人类单抗的快速发现 感染是普罗米修斯联盟开发免疫预防和 治疗医学对策(MCM)。我们的翻译卓越中心 研究将重点开发用于三组NIAID A类优先事项的MCM 病原体(埃博拉病毒、克里米亚-刚果出血热病毒和汉坦病毒)。 埃博拉病毒是丝状病毒科的成员,会在人类和 非人灵长类,人类病死率高达90%。正如2013年的- 2016年埃博拉病毒病在西非流行,埃博拉病毒构成重大公共卫生 威胁。克里米亚-刚果出血热病毒是布尼亚病毒科的成员, 在高达50%的人类感染中会导致致命出血。汉坦病毒也属于 布尼亚病毒科,感染每年与超过15万例疾病有关 病死率为30%。鉴于这些病毒造成的疾病严重程度,MCM是 急需之物。 高免血清对动物模型和人体的强烈保护作用 表明人类感染和感染这些病毒组的疾病将容易受到 以单抗为基础的治疗和预防。项目II将促进单抗的发现 通过开发分离和分离所需的分子工具(目标1)在项目I中所做的努力 鉴定来自人类幸存者的候选治疗性单抗。我们的重点将放在 新型重组抗原和BSL-2病毒替代物的制备及其在单次B细胞白血病中的应用 细胞分选实验。这些生物制剂对表征过程(目标2)也至关重要 将确定单抗表位、竞争组、结构和作用机制,以及未来 核心B中的产品化验开发。项目二产生的数据,结合效力和 来自项目I的协同数据将允许简化和机械地向下选择 最有希望实现Fc效应功能的候选单抗和单抗组合 在核心C对引线进行活体评估之前进行分析和优化(目标3)项目II还将 参与敲定最佳铅免疫预防单抗,以在项目III和 免疫治疗性单抗将在核心B内部进入高级开发阶段。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kartik Chandran其他文献

Kartik Chandran的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kartik Chandran', 18)}}的其他基金

Einstein BSL3 Laboratory Renovation to Advance Biomedical Research on RNA Viruses of Pandemic Potential
爱因斯坦 BSL3 实验室改造将推进对可能引发大流行的 RNA 病毒的生物医学研究
  • 批准号:
    10611691
  • 财政年份:
    2022
  • 资助金额:
    $ 166.21万
  • 项目类别:
Comprehensive genetic dissection of poxvirus membrane assembly and function
痘病毒膜组装和功能的全面基因解剖
  • 批准号:
    10575027
  • 财政年份:
    2022
  • 资助金额:
    $ 166.21万
  • 项目类别:
Optimizing SARS-CoV-2 wastewater based surveillance in urban and university campus settings.
优化城市和大学校园环境中基于 SARS-CoV-2 废水的监测。
  • 批准号:
    10320993
  • 财政年份:
    2021
  • 资助金额:
    $ 166.21万
  • 项目类别:
Optimizing SARS-CoV-2 wastewater based surveillance in urban and university campus settings.
优化城市和大学校园环境中基于 SARS-CoV-2 废水的监测。
  • 批准号:
    10264634
  • 财政年份:
    2021
  • 资助金额:
    $ 166.21万
  • 项目类别:
Structure-based Vaccine Design for CCHFV
基于结构的 CCHFV 疫苗设计
  • 批准号:
    10405068
  • 财政年份:
    2020
  • 资助金额:
    $ 166.21万
  • 项目类别:
Structure-based Vaccine Design for CCHFV
基于结构的 CCHFV 疫苗设计
  • 批准号:
    10624297
  • 财政年份:
    2020
  • 资助金额:
    $ 166.21万
  • 项目类别:
Structure-based Vaccine Design for CCHFV
基于结构的 CCHFV 疫苗设计
  • 批准号:
    10202440
  • 财政年份:
    2020
  • 资助金额:
    $ 166.21万
  • 项目类别:
Project II: Biologics Engineering and Antibody Mechanism of Action
项目二:生物制剂工程与抗体作用机制
  • 批准号:
    10555312
  • 财政年份:
    2019
  • 资助金额:
    $ 166.21万
  • 项目类别:
Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats
Prometheus:快速开发针对新兴病毒威胁的基于人类抗体的治疗和预防方法的平台
  • 批准号:
    10088385
  • 财政年份:
    2019
  • 资助金额:
    $ 166.21万
  • 项目类别:
Core B: Industrialization Core
核心B:工业化核心
  • 批准号:
    10088388
  • 财政年份:
    2019
  • 资助金额:
    $ 166.21万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 166.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 166.21万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 166.21万
  • 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 166.21万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 166.21万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 166.21万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 166.21万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 166.21万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 166.21万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 166.21万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了